Skip to content

Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer

Organ-preserving Management in Patients With Complete or Near-complete Tumour Response After Preoperative Radio(Chemo)Therapy for Rectal Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04095468
Enrollment
215
Registered
2019-09-19
Start date
2017-09-18
Completion date
2026-01-01
Last updated
2019-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rectal Cancer, Rectal Neoplasms

Keywords

rectal cancer, preoperative radiotherapy, organ preservation, watch-and-wait

Brief summary

Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in reporting the proportion of patients achieving clinical complete response (cCR) after routinely delivered preoperative radio(chemo)therapy, likely because of patients' selection. This proportion in population-based level is poorly defined. In addition, predictive factors for cCR are also poorly defined. It is known that cCR response is observed often in small tumours. However, cCR proportion in large cancers has not been sufficiently evaluated. For example, even though pathological complete response (pCR) does occur in large fixed cancer, it is unknown whether cCR does also occur because persistent fibrous stroma may mimic residual cancer in all of such cases. This is a prospective observational population-based cohort study on low rectal cancer to answer the question of how often clinical or near-clinical tumour response occur after routinely delivered preoperative radiotherapy in relation to the pre-treatment tumour characteristics. The additional question was how often pCR occur in relation to the pre-treatment tumour characteristics in the patients managed by total mesorectal excision because of persistent tumour after radiotherapy. The additional aim was the implementation of watch-and-wait strategy or full-thickness local excision (as an option instead of total mesorectal excision in the patients with sustained near-cCR) within a frame of a prospective study. In the patients managed by organ preservation, the secondary outcome measures were: i) local regrowth rate, ii) effectiveness of salvage surgery, iii) disease-free survival at 3 years and overall survival at 5 years, iv) anorectal function.

Interventions

RADIATIONPreoperative Radio(Chemo)Therapy

Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait

Sponsors

Polish Society of Surgical Oncology
CollaboratorUNKNOWN
Maria Sklodowska-Curie National Research Institute of Oncology
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Primary rectal cancer * Low tumour (accessible by digital rectal examination) * Routine preoperative radio(chemo)therapy according to the institutional policy; short-course radiation and immediate surgery is not allowed. * Informed consent for watch-and-wait strategy or local excision in patients with cCR and near-cCR

Exclusion criteria

* Recurrent cancer * Cancers situated in the upper rectum * Distant metastases

Design outcomes

Primary

MeasureTime frameDescription
Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.12 weeks from the start of radiotherapy
Percentages of cCR and near-cCR in the patients with resectable cancer11 weeks from the start of radiotherapy
Percentages of cCR and near-cCR in the patients with threatened mesorectal fascia.11 weeks from the start of radiotherapy
Percentages of cCR and near-cCR in relation to the selected tumour characteristics.11 weeks from the start of radiotherapyThe selected tumour characteristics: TN categories, tumour length, degree of circumferential involvement, tumour mobility on digital rectal examination (mobile, tethered, fixed) and status of mesorectal fascia (threatened or not).

Secondary

MeasureTime frameDescription
Local regrowth rate5 years
Disease-free survival3 years
Overall survival5 years
Anorectal function assessed by low anterior resection syndrome (LARS) score3 yearsThe questionnaire will be completed by patients. It includes 5 items related to anorectal function. The range of the score (0-42) is divided into 0 to 20 (no LARS), 21 to 29 (minor LARS) and 30 to 42 (major LARS).

Countries

Poland

Contacts

Primary ContactKrzysztof Bujko, M.D. PhD
Krzysztof.Bujko@coi.pl+48601207466

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026